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Abstract
Background: There has been much interest in differentiating diseased and normal samples using biomarkers derived from
mass spectrometry (MS) studies. However, biomarker identification for specific diseases has been hindered by
irreproducibility. Specifically, a peak profile extracted from a dataset for biomarker identification depends on a data pre-
processing algorithm. Until now, no widely accepted agreement has been reached.
Results: In this paper, we investigated the consistency of biomarker identification using differentially expressed (DE) peaks
from peak profiles produced by three widely used average spectrum-dependent pre-processing algorithms based on SELDI-
TOF MS data for prostate and breast cancers. Our results revealed two important factors that affect the consistency of DE
peak identification using different algorithms. One factor is that some DE peaks selected from one peak profile were not
detected as peaks in other profiles, and the second factor is that the statistical power of identifying DE peaks in large peak
profiles with many peaks may be low due to the large scale of the tests and small number of samples. Furthermore, we
demonstrated that the DE peak detection power in large profiles could be improved by the stratified false discovery rate
(FDR) control approach and that the reproducibility of DE peak detection could thereby be increased.
Conclusions: Comparing and evaluating pre-processing algorithms in terms of reproducibility can elucidate the relationship
among different algorithms and also help in selecting a pre-processing algorithm. The DE peaks selected from small peak
profiles with few peaks for a dataset tend to be reproducibly detected in large peak profiles, which suggests that a suitable
pre-processing algorithm should be able to produce peaks sufficient for identifying useful and reproducible biomarkers.
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Introduction
Proteomic technologies based on mass spectrometry (MS) [1]
have increasingly become the method of choice for the
identification of biomarkers that are useful for differentiating
diseased and normal samples [2,3,4]. However, similar to
microarray studies [5,6], the use of MS techniques to identify
disease biomarkers has been hindered by irreproducibility [7,8].
For example, the biomarkers identified in four prostate cancer
studies are very different [8]. Recently, Callesen et al. [7] showed
that only 10 of 207 biomarkers reported in 15 MS-based breast
cancer studies were detected in more than 2 studies. This
irreproducibility raises questions about the biological significance
and clinical implications of the detected biomarkers.
Many factors, such as sample processing and operating
procedures for the experiments, can affect the reproducibility of
disease biomarkers [9,10,11,12,13,14,15]. Importantly, the data
pre-processing algorithm chosen to produce peak profiles may
greatly affect biomarker identification [16]. Some studies have
attempted to find the optimum pre-processing algorithm for
detecting peaks [17,18,19]. However, until now, no widely
accepted agreement has been reached. For example, based on
simulated data with predefined true peaks, Cruz-Marcelo et al.
[17] and Emanuele et al. [18] evaluated several algorithms in terms
of both sensitivity (defined as the proportion of true peaks that
were correctly identified) and specificity (defined as the false
discovery rate (FDR)). These two studies reached different
conclusions on the three algorithms that they both evaluated,
which were MassSpecWavelet [20], Cromwell [21] and commer-
cial software produced by Ciphergen Biosystems. Cruz-Marcelo
et al. [17] reported that these algorithms offered high sensitivity
with a low FDR, whereas Emanuele et al. [18] showed that they
had low sensitivity and a low FDR. This conflict could have been
introduced by differences in their simulation data, which in
general tend to be biased to specific scenarios. A solution for
avoiding bias is to adopt real data instead of simulated data.
Unfortunately, with real data, the sensitivity and FDR of an
algorithm cannot be evaluated because the true peaks are
unknown. However, pre-processing algorithms can be compared
in terms of peak detection reproducibility by assessing peak
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validating biological discoveries that is distinct from sensitivity
and specificity [6,22,23,24].
In this study, using real prostate and breast cancer data, we first
evaluated the reproducibility of peak detection among three widely
used pre-processing algorithms that detect peaks dependent on the
average spectrum of all of the spectra (see Methods), including
SpecAlign [25], MassSpecWavelet [20] and Cromwell [21]. More
importantly, we further evaluated the reproducibility of detection
of differentially expressed (DE) peaks (often defined as biomarkers),
which has been a focus of the biological community but have not
been fully evaluated with either simulated or real data. Our results
indicate that the number of peaks detected for a dataset varies
dramatically depending on the pre-processing algorithm. Our
results also revealed two important factors affecting the consistency
of DE peak identification using different pre-processing algo-
rithms. The first factor is that a peak profile may lack DE peaks
found in another profile, which can affect reproducibility before
the selection of DE peaks. The second factor is that a large peak
profile with many peaks may suffer from low statistical power for
identifying DE peaks because of the large scale of the test together
with small sample number [26,27,28,29]. Fortunately, our results
indicate that the power of large peak profiles can be increased by
the stratified FDR control approach [30]. Consequently, DE peaks
selected from small peak profiles tend to be reproducibly detected
in large peak profiles. Based on the analysis of this study, we
suggest that a suitable pre-processing algorithm should be able to
produce peaks sufficient for the identification of useful and
reproducible biomarkers.
Materials and Methods
Cancer datasets
The prostate cancer data, which was downloaded from http://
www.evms.edu/vpc/seldi/, consisted of duplicate spectra for 168
cancer and 81 normal serum samples measured by SELDI-TOF
MS (IMAC-3 chips), with the mass-to-charge (m/z) ratio ranging
from 0 to 200 kDa [31]. The blood samples of diagnosed stage I-
IV patients were procured from the Department of Urology,
Eastern Virginia Medical School and the samples of healthy men
were obtained from free screening clinics open to the general
public (see details in [31]). The serum samples were obtained from
the Virginia Prostate Center Tissue and Body Fluid Bank. The
breast cancer data, which was downloaded from http://bioinfor-
matics.mdanderson.org/pubdata.html, consisted of duplicate spec-
tra for 26 cancer and 14 normal plasma samples measured by
SELDI-TOF MS (IMAC-Cu chip), with the m/z ratio ranging
from 10 to 100 kDa [32]. The blood samples were obtained from
diagnosed stage I-III breast carcinoma patients and healthy
volunteers (see details in [32]). The plasma samples were
conducted at the Nellie B. Connally Breast Center at the
University of Texas M. D. Anderson Cancer Center.
For each pair of duplicate spectra, the two spectra were pre-
processed separately and then averaged to produce a consensus
profile. Considering measurement noise and detection limitations,
we only used those peaks in the m/z range of 1–10 kDa for breast
cancer and 2–40 kDa for prostate cancer in our analyses as in the
original papers [31,32].
Data pre-processing algorithms
As illustrated in Figure 1, SELDI-TOF-MS data are usually
pre-processed by multiple steps including denoising (smoothing),
baseline subtraction, normalisation, peak detection, clustering of
peaks and peak quantification [17]. The three algorithms analysed
in this study detect peaks according to the average spectrum of all
the spectra, and the pre-processing procedures are described
below. The specific parameter settings used for each algorithm can
be found in Text S1.
(1). SpecAlign [25] pre-processes data as follows: a) spectrum
smoothing using the Savitzky-Golay filter; b) subtracting the
baseline estimated by a restrained moving average; c) rescaling
intensities to positive values by making the minimum value 0; d)
normalising intensities to let all spectra have the same total ion
current; e) generating an average spectrum; f) using the fast
Fourier transform (FFT)/peak matching combined method to
align the detected peaks of individual spectra to those identified in
the average spectrum; and g) picking peaks. The default height
ratio that served as the signal-to-noise ratio (SNR) was 1.5.
(2). The MassSpecWavelet package for peak detection [20]
combined with the PROcess package for peak quantification [33]
(denoted MSW/PRO). MassSpecWavelet has been reported to
have high sensitivity with a low FDR for peak detection [17].
However, it does not quantify the detected peaks. Thus, based on
work by Cruz-Marcelo et al. [17], we used PROcess to quantify
peaks detected by MassSpecWavelet. MassSpecWavelet detects
peaks using the continuous wavelet transformation on the average
spectrum of all of the spectra. For each spectrum, PROcess
subtracts the baseline, which is estimated by linear interpolation,
then normalises the intensities using the median area under the
curves of all of the spectra, and finally quantifies the detected peaks
of individual spectra by the local maximum within the predefined
interval. The default SNR for peak detection was 3.
(3). Cromwell [21] pre-processes data by a) computing an
average spectrum; b) denoising the average spectrum by the
undecimated discrete wavelet transform; c) correcting intensities
for the average spectrum by subtracting the baseline, which is
estimated by a monotone minimum curve; d) finding peaks with
local maximal intensities for the average spectrum; e) repeating b)
and c) for each spectrum, normalising intensities with average total
ion current, and quantifying peak intensities using the maximum
within the intervals defining peaks on the average spectrum; and f)
extracting peaks with a user-defined SNR. The default SNR was
set at 5, according to the recommendation of the developers.
The output of a pre-processing algorithm is a peak profile for
the dataset, which is composed of the detected peaks and their
corresponding intensities in each spectrum. For simplicity, the
peak profiles produced by SpecAlign, MSW/PRO and Cromwell
are denoted SpecAlign profile, MSW/PRO profile and Cromwell
profile, respectively.
Two peaks with a m/z ratio difference within a shift range may
correspond to the same biological molecule [17,34]. In this study,
we used shift ranges of 60.1%, 60.2% and 60.3%, and the
results were similar. For simplicity, we only present the results
based on the commonly used shift range of 60.3% [17,18,33].
Because the optimisation goals for peak detection are not
defined in real data, the default parameter settings for pre-
processing algorithms are used for detecting peaks in most
applications. However, some studies may tune the SNR to find
more or less peaks [17,18,35,36]. Thus, we similarly tuned the
SNR in our study to compare pre-processing algorithms. In
addition, because a lower SNR may detect more true and useful
peaks, we mainly considered the lower of the two SNRs when
comparing one algorithm with another (see details in the
Discussion).
Detection of DE peaks and consistency scores
Student’s t-test was used to evaluate the significance of the
differences between the intensity means of the cancer and normal
Reproducible Biomarker in SELDI-TOF MS
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Hochberg procedure to control the FDR at a given level [37].
The consistency of two peak lists was measured by the PO
(percentage of overlaps) score [38]. Supposing list 1 with l1 peaks
and list 2 with l2 peaks share k peaks, then the PO score from list 1
(or 2) to list 2 (or 1) is PO12= k/l1 (or PO21= k/l2). Because the PO
score depends on the list lengths, we also calculated the normalised
PO score (nPO), which is defined as the proportion of the observed
score beyond chance to the corresponding maximum potential
score beyond chance [38]:
nPO12~
PO12{EP O 12 ðÞ
1{EP O 12 ðÞ
ð1Þ
nPO21~
PO21{EP O 21 ðÞ
1{EP O 21 ðÞ
ð2Þ
where E(PO12) (or E(PO21)) was estimated as the average of the
PO12 (or PO21) scores for 1,000 pairs of peak lists (with lengths l1
and l2) extracted randomly from the two raw m/z lists. Among the
scores for the 1,000 random pairs of peak lists, the p-value of
observing the PO score by random chance was calculated as the
proportion of the scores not less than the observed score.
The PO (nPO) score between two lists of DE peaks was
calculated by the same approach as described above, except that a
DE peak was defined as being shared by two lists only if it was
regulated in the same direction in both peak profiles [38]. E(PO)
was evaluated using DE peak lists randomly extracted from the
two peak profiles. Here, we present the PO (nPO) score from the
shorter list to the longer list and evaluate the degree that the
shorter list is covered by the longer list.
We denote the PO (nPO) score from the peaks detected by
algorithm A to those detected by algorithm B as POAB (nPOAB),
while PO
DE
AB (nPO
DE
AB ) is for DE peaks.
Stratified FDR control approach
In large-scale testing with current multiple testing adjustments,
the power might decrease as the number of tests increases
[27,30,39]. To increase the power, a stratified FDR control
approach has been proposed [24]. As a proof of principle, we
analysed whether the consistency of DE peak detection can be
increased by improving the ability to identify DE peaks in large
peak profiles using the stratified FDR control approach, which is
based on the assumption that peaks with large fold change (FC)
values may be more likely to be true DE peaks [40]. First, we
applied the k-means clustering algorithm to partition the peaks
into k groups, by minimising the sum of the squared Euclidean
distance between the FC value for each peak and its nearest cluster
Figure 1. Illustration of a pre-processing procedure. (A) Raw spectrum. (B) Smoothed spectrum. The baseline estimated from the smoothed
spectrum is represented as the gray line. (C) Normalized spectrum. The baseline is subtracted from the smoothed spectrum. Then, the baseline-
subtracted spectrum is normalized. The peaks detected based on the normalized spectrum appear in circles.
doi:10.1371/journal.pone.0026294.g001
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a maximal mean of silhouette values, which measures how similar
a peak is to other peaks in its own group compared with those in
other groups [42]. Then, at a particular FDR control level, we
selected DE peaks in each group. As there is no overlap between
the discoveries from different groups, the FDR of the integrated
results is still less than the given FDR level [30].
Results
Reproducibility of peak detection
In the following, the results for each algorithm were based on its
default SNR unless otherwise mentioned. For the prostate cancer
dataset, 31 and 53 peaks were detected by SpecAlign and MSW/
PRO, respectively, and all of them were included in the 420 peaks
detected by Cromwell. Furthermore, we evaluated the reproduc-
ibility of peak detection using the same number of peaks by
decreasing the SNR of one of the two algorithms. However, even
using the lowest SNRs of 1 and 0.1 allowable for SpecAlign and
MSW/PRO, respectively, only 130 and 90 peaks were detected.
Most were included in the peaks detected by Cromwell with POSC
(nPOSC) and POMC (nPOMC) scores as high as 1 (1) and 0.93
(0.93), respectively (Figure 2A). For the comparison between
SpecAlign and MSW/PRO, the POSM (nPOSM) score was 0.84
(0.84). When the SNR was decreased to 1.27, SpecAlign detected
the same number of peaks (53) as MSW/PRO, but the score
decreased to 0.74 (0.73) (Figure 2A).
For the breast cancer dataset, 19 and 47 peaks were identified
by SpecAlign and MSW/PRO, respectively, and all of them were
included in the 287 peaks detected by Cromwell. Furthermore, as
shown in Figure 2B, even after decreasing the SNR to the lowest
allowable values for SpecAlign and MSW/PRO, only 104 and 52
peaks, respectively, were detected, and all of them were detected
by Cromwell. The consistency score between SpecAlign and
MSW/PRO was not high, with a POSM (nPOSM) score of 0.68
(0.68). After the SNR was decreased to 1.181, SpecAlign detected
the same number of peaks (47) as MSW/PRO, and the POSM
(nPOSM) score decreased to 0.55 (0.55) (Figure 2B).
The above results suggest that when using the default SNR for
each algorithm in these two datasets, SpecAlign and MSW/PRO
tend to be less sensitive at peak detection than Cromwell. All of the
detected peaks also tend to be detected by Cromwell. Cromwell
could still capture almost all of the peaks detected by SpecAlign
and MSW/PRO when the SNRs of the latter two less sensitive
algorithms were lowered.
Reproducibility of DE peak detection
We then evaluated the reproducibility of DE peak identification
in peak profiles produced by different pre-processing algorithms.
For the prostate cancer dataset, 27 and 24 DE peaks were selected
from the SpecAlign and MSW/PRO profiles, respectively, with a
10% FDR control. Most of these were also present in the
229 DE peaks identified from the Cromwell profile, and the PO
DE
SC
(nPO
DE
SC ) and PO
DE
MC (nPO
DE
MC) scores were 0.81 (0.62) and 0.96
(0.92), respectively. Although all of the peaks in the SpecAlign
profile were included in the Cromwell profile, more than 10% of
the selected DE peaks were not included in the DE peaks found in
the Cromwell profile. After the SNRs were decreased for
SpecAlign and MSW/PRO, the consistency between the DE
peaks from these two peak profiles and those of the Cromwell
profile decreased slightly (Figure 3A and 3B). The consistency
between the 27 and 24 DE peaks detected in the SpecAlign
and the MSW/PRO profiles was relatively low, with a PO
DE
MS
(nPO
DE
MS) score of 0.54 (0.31). However, after the SNR was
decreased for SpecAlign, the score increased to 0.79 (0.61) as more
peaks were included in the enlarged SpecAlign profile and were
detected as DE peaks (Figure 3C).
Figure 2. Reproducibility of peak detection across pre-processing algorithms. (A) For prostate cancer and (B) for breast cancer.
Reproducibility was evaluated between one algorithm (x-axis label) with various SNRs and another (title) with the default SNR. The default SNRs for
SpecAlign, MSW/PRO and Cromwell were 1.5, 3 and 5, respectively. The filled triangles represent the number of peaks (right y-axis) detected by the
algorithm, which is shown by the x-axis label. All PO (nPO) scores were significantly higher than expected by chance (p,2.2E-11).
doi:10.1371/journal.pone.0026294.g002
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DE peaks were selected from the SpecAlign profile, and they were
included in the 8 DE peaks selected from the MSW/PRO profile
with a PO
DE
SM (nPO
DE
SM) score of 1 (1). After the SNR was decreased
for SpecAlign, similar results were observed (Figure 3D). However,
no DE peaks were selected from the Cromwell profile.
Two major factors affect the consistency of DE peak
identification
Our analysis revealed two major factors that can affect the
consistency of DE peak identification using different pre-
processing algorithms. The first factor is that some DE peaks
selected from one peak profile may not be included in another
peak profile. For example, for the prostate cancer dataset, with a
10% FDR control, 11 of the 24 DE peaks identified from the
MSW/PRO profile were not included in the SpecAlign profile.
Notably, after the SNR of SpecAlign decreased to 1.27, 6 of these
11 DE peaks were included in the SpecAlign profile and selected
as DE peaks, which led to increased reproducibility (Figure 3C).
Obviously this factor greatly affects the consistency of DE peak
identification. The second factor is that the statistical power of
identifying DE peaks in different peak profiles varies. Thus, some
peaks shared by two peak profiles might be detected as DE peaks
in one profile but not in another. The statistical power can be
affected by many variables, such as peak quantification, the
number of peaks for testing, the sample size, the proportion of true
positives and the FDR control level [6,26,27,28]. Here, we mainly
analysed the effects of the number of tests and sample size on
power.
First, we used an example to illustrate the effect of the number
of tests. In the breast cancer dataset, at a 10% FDR control level,
no DE peaks were detected in the whole Cromwell profile, which
consisted of 287 peaks. However, when considering a subprofile of
the Cromwell profile composed of all the peaks included in the
MSW/PRO profile, 6 DE peaks were detected and they were all
included in the 8 DE peaks identified in the MSW/PRO profile.
Notably, the t-test p-value cutoff for declaring significance based
on the Benjamini-Hochberg FDR procedure [37] was 0.013, but it
decreased to 0.0003 in the whole Cromwell profile, which resulted
in zero power for finding DE peaks (i.e., no DE peaks were found).
Similarly, when considering a subprofile of the Cromwell profile
composed of all of the peaks of the SpecAlign profile, 2 DE peaks
were detected at the 10% FDR control level, and they were
identical to the 2 DE peaks identified from the SpecAlign profile.
To illustrate the effect of sample size, we randomly sampled
subsets at various sample size levels from the prostate cancer
dataset of 249 samples. At each sample size level, we randomly
sampled 100 subsets with the proportions of normal and cancer
samples in each subset held identical to those in the raw dataset.
As the sample size increased, the number of DE peaks selected
with a 10% FDR control in the peak profile produced by each pre-
processing algorithm increased, which indicates that the power to
detect DE peaks increased (Figure 4). Consequently, the
consistency of the DE peaks selected using the different pre-
processing algorithms increased greatly.
Improving reproducibility by increasing statistical power
As shown above for the breast cancer dataset, the complete lack
of statistical power for identifying DE peaks in some large peak
profiles is an important factor affecting the consistency of DE peak
detection. As a proof of principle, we demonstrated that the ability
to find DE peaks in the Cromwell breast cancer profile could be
improved by the stratified FDR control approach, which can
increase the consistency between the identified DE peaks and
Figure 3. Reproducibility of DE peak detection across pre-processing algorithms. (A), (B), (C) for prostate cancer and (D) for breast cancer.
Reproducibility was evaluated between one algorithm (x-axis label) with various SNRs and another (title) with the default SNR. The default SNRs for
SpecAlign, MSW/PRO and Cromwell are 1.5, 3 and 5, respectively. The DE peaks were selected with a 10% FDR control. The filled diamonds represent
the number of DE peaks (right y-axis) detected using the algorithm shown by the x-axis label. All PO
DE (nPO
DE) scores were significantly higher than
expected by chance (p,7.0E-3).
doi:10.1371/journal.pone.0026294.g003
Reproducible Biomarker in SELDI-TOF MS
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26294those selected from the SpecAlign and MSW/PRO profiles. Using
the k-means clustering algorithm as described in the Methods, the
287 peaks detected in the Cromwell profile were clustered into 2
groups. One group contained 259 peaks with low FC values, and
the other group contained 28 peaks with high FC values. With a
stratified FDR level of 10%, a total of 16 DE peaks were detected,
which included most of the DE peaks detected in the Spec-
Align and MSW/PRO profiles using the default SNRs with a
PO
DE
SC (nPO
DE
MC) and PO
DE
MC (nPO
DE
MC) of 1 (1) and 0.75 (0.74),
respectively. By lowering the SNRs for SpecAlign and MSW/
PRO, similar results were generally obtained (Figure 5). However,
after the SNR decreased to 1 for SpecAlign, the PO
DE
SC (nPO
DE
SC)
score was only 0.5 (0.47). This result indicates that the stratified
FDR control approach can greatly increase detection power, but
there is still some room for improvement.
However, with the Cromwell prostate cancer profile, the
stratified and simple FDR control approaches had the same
power (i.e., they detected the same DE peaks). This result may be
because the power of the simple FDR control approach to identify
DE peaks was already high.
Comparison with biomarkers reported in the original
breast cancer study
A total of 5 DE peaks were reported in the original study of the
breast cancer dataset [32]. Briefly, the pre-processing procedure
used in the original paper included the Savitzky-Golay filter,
baseline subtraction, normalisation to the same total ion current
and extracting peaks with SNR no less than 3.0, and the DE peaks
were selected with a t-statistic score .3.5. We evaluated whether
these 5 DE peaks could be reproduced using the three pre-
processing algorithms with their default SNRs. When the
SpecAlign algorithm was used, only 2 of these 5 DE peaks were
detected as peaks and then detected as DE peaks at the 10% FDR
control. Using the MSW/PRO algorithm, all 5 DE peaks were
identified as peaks and then detected as DE peaks. Using the
Cromwell algorithm, all 5 DE peaks were detected as peaks, but
none was selected as a DE peak at the FDR level of 10% by the
simple FDR control approach. However, all 5 DE peaks were
included in the 16 DE peaks selected using the Cromwell
algorithm at the FDR level of 10% when using stratified FDR
control.
Discussion
Reproducibility is of fundamental importance for the validation
of biological discoveries from high-throughput data. In MS
studies, pre-processing algorithms may greatly affect biomarker
discovery. Using biological data for cancer, our study showed that
the number of peaks identified in a dataset varies depending on the
pre-processing method. It also revealed that the consistency of DE
peak identification is affected by two important factors, the
absence of some DE peaks in another peak profile and the reduced
statistical power of DE peak identification in profiles with a large
number of peaks but a small number of samples. Our findings
indicate that DE peaks selected from small peak profiles tend to be
reproducibly detected in large profiles when sufficient power for
identifying DE peaks in large profiles is achieved through powerful
statistical approaches, such as the stratified FDR control approach.
The analyses in this study could be extended to other MS-based
proteomic technologies. For example, for tandem mass spectrom-
Figure 4. Average number of DE peaks and average PO
DE
(nPO
DE) score at various sample sizes for prostate cancer. The
default SNR was used for each pre-processing algorithm. At each
sample size, the average number of DE peaks detected at a 10% FDR
control was calculated based on 100 randomly sampled subsets. The
filled squares, triangles and diamonds represent the average number of
DE peaks (right y-axis) detected using SpecAlign, MSW/PRO and
Cromwell, respectively.
doi:10.1371/journal.pone.0026294.g004
Figure 5. Reproducibility of DE peak detection across pre-
processing algorithms. Using Cromwell at the default SNR, the
stratified FDR control approach detected 16 DE peaks at the 10% level.
For SpecAlign and MSW/PRO, the simple FDR control approach was
used to select DE peaks. All PO
DE (nPO
DE) scores were significantly
higher than expected by chance (p,0.013). For a detailed description of
the figures see the legend to Figure 3.
doi:10.1371/journal.pone.0026294.g005
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peak detection and different search engines for matching proteins
could produce varied protein profiles [43]. Thus, the two factors
revealed in this study could also affect the consistency of biomarker
detection in MS/MS studies.
Based on a simulation study, Cruz-Marcelo et al. [17] suggested
that the combination of MassSpecWavelet and PROcess offers
high sensitivity with a low FDR for peak detection. However,
based on our analysis of the reproducibility of peak and DE peak
detection based on two real datasets, the MSW/PRO algorithm
(i.e. the combination of MassSpecWavelet and PROcess) tended to
detect fewer peaks than Cromwell, which indicated that it might
be less sensitive for peak detection and might miss some DE peaks
detectable by using Cromwell. In addition, we evaluated the
reproducibility of the three average spectrum-dependent algo-
rithms used in this study with the widely used commercial software
ProteinChip Software 3.2.1 and Biomarker Wizard (denoted as
Ciphergen) for the breast cancer dataset. The required raw data
from the original study were not available for Ciphergen to
evaluate the prostate cancer dataset. The results showed that the
Ciphergen algorithm tended to be more sensitive for peak
detection than SpecAlign or MSW/PRO, and most of the peaks
detected by these three algorithms also tended to be detected by
Cromwell (see details in Text S1 and Figure S1); similar results
were for DE peak detection (Text S1 and Figure S2). Notably,
these results based on limited real data and those based on
simulated data may only weakly reflect the performance of these
pre-processing algorithms on data with different characteristics.
Thus, we still cannot conclusively state that a specific algorithm is
optimal for pre-processing all data. Nevertheless, based on our
results, we can suggest a guideline for selecting a suitable pre-
processing algorithm. To find useful and reproducible biomarkers,
the algorithm should be able to produce sufficient peaks and
achieve high sensitivity in peak detection. One problem is that a
large peak profile is likely to include more random signals (false
peaks), which may decrease the power of the subsequent detection
of DE peaks in this profile. However, this problem can be
alleviated by the use of statistically powerful approaches such as
the stratified FDR control approach. In addition, increasing
sample size can improve the power and, consequently, the
reproducibility of DE peak detection. Thus, when sufficient power
can be achieved through a powerful statistical approach or a large
sample size, Cromwell can capture more biomarkers than the
other pre-processing algorithms analysed in this study.
ThefactthatsomeDEpeaksselectedfromonepeakprofilearenot
identified as peaks in another profile may suggest that these DE peaks
have relatively low intensities. Thus, they might be less interesting in
clinical applications. However, many biologically interesting mole-
cules relevant to diseases are low-abundance proteins in human
biofluids such as serum and plasma [44]. Some low-abundance
proteins, such as the prostate-specific antigen (PSA) for prostate
cancer [44] and human epidermal growth factor receptor 2 (HER2)
for breast cancer [45], have been selected as clinical biomarkers.
Discovering such low-abundance biomarkers is an important
application of MS-based proteomic technologies [46,47].
In addition to the factors revealed in this study, other factors
may also affect the reproducibility of DE peak detection. For
example, molecular isotopes with different charges could induce
an improper alignment of spectra and produce multiple peaks in a
spectrum [48], which could reduce the power and eventually the
reproducibility of DE peak detection. Dijkstra et al. [48] proposed
an algorithm to reduce the number of multiple-charge peaks for
the underlying molecules, and this may increase the power and
reproducibility of DE peak detection.
Other approaches might also improve the power of selecting DE
peaks with FDR control for multiple testing. For example, by only
considering peaks with large changes between diseased and normal
samples, the power could increase as the number of tests decreases
[40]. However, this approach considers only a portion of the total
tests, and some true positives may be lost. In contrast, the stratified
FDR control approach considers all of the tests. However, its
performance depends on the criteria for data stratification. In
addition to the simple k-means clustering algorithm used in this
study, other stratification approaches, such as hierarchical cluster-
ing, could be used. Currently, finding the optimal stratification
remains an openquestion [30,49,50,51]that warrants further study.
In this study, we analysed the consistency of biomarkers
identified in different peak profiles for a single MS dataset pre-
processed by different algorithms. Usually, the sample handling
protocol is identical for all samples in a study (see the detailed
sample handling protocols for the two datasets used in this study in
[31] and [32]). In this situation, the computational normalization
can be applied to reduce the unknown variability of samples
[52,53]. Notably, a more challenging task is to analyse the
reproducibility of biomarker discovery across different studies
(datasets) for a disease [9,11]. It is known that intensities of
proteins depend on sample handling protocols. For example, the
clotting time can affect the intensities of proteins related to the
clotting of blood [15]. The computational normalization can not
correct such variability. Therefore, the establishment of standard
operating procedures for serum and plasma collection is very
important for enhancing the reproducibility of SELDI data and
thereby for improving the reproducibility of biomarker discovery
across different studies [54]. Alternatively, an experimental
normalization approach using known protein (peptides) can be
applied to correct the variability induced by sample handling
[55,56]. Notably, the known proteins (peptides) need to be
carefully selected to balance the trade-off between reducing the
variability of the types of proteins to which they belong and
increasing the intensity bias of the other types of proteins [57]. In
addition, the consistency between biomarker lists identified from
different studies is usually measured by counting the overlaps, such
as in this study. However, observing low overlap across biomarker
lists identified from different high-throughput datasets is highly
likely because the sample sizes of current studies are often
insufficient to fully capture large biological variations [6,26].
Because complex diseases are often characterised by many
functionally correlated molecular changes [58,59], we have
proposed consistency scores for evaluating the reproducibility of
disease biomarker discovery at the systems biology level [38,60]. In
the future, by applying these consistency scores, we plan to
evaluate the reproducibility of DE peaks detected in different MS-
based studies for a disease, an approach that is currently limited by
the fact that few MS datasets for cancer are publicly available [61].
Supporting Information
Figure S1 Reproducibility of peak detection between
the average spectrum-dependent algorithms and Ci-
phergen for the breast cancer dataset. The reproducibility
was evaluated between one algorithm (x-axis label) with various SNRs
and another (title) with the default SNR. The default SNRs for
SpecAlign, MSW/PRO, Cromwell and Ciphergen were 1.5, 3, 5 and
5, respectively. The filled triangles represent the number of peaks
(right y-axis) detected by the algorithm shown by the x-axis label. All
PO (nPO) scores were significantly higher than expected by chance
(p,7.5E-12).
(TIF)
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tween the average spectrum-dependent algorithms and
Ciphergen for the breast cancer dataset. For Ciphergen
with the default SNR, the stratified FDR control approach
detected 7 DE peaks at the level of 10%. For SpecAlign and
MSW/PRO, the simple FDR control approach was used to select
DE peaks. All PO
DE (ncPO
DE) scores were significantly higher
than expected by chance (p,9.0E-3). For a detailed description of
the figures see the legend to Figure 3 in the main text.
(TIF)
Text S1 Parameter settings of pre-processing algo-
rithms for peak detection and quantification; reproduc-
ibility between the three average spectrum-dependent
algorithms and ProteinChip Software 3.2.1 and Bio-
marker Wizard.
(DOC)
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